News in Considerable Facts: 3M Company (NYSE:MMM), Verizon Communications Inc. (NYSE:VZ), BIND Therapeutics, Inc. (NASDAQ:BIND)

3M Company (NYSE:MMM) released that it has signed into a definitive contract to purchase Capital Safety from KKR for a total enterprise value of $2.5B, comprising the assumption of around $0.7B of debt, net of cash purchased. Capital Safety is a global provider of dropped protection equipment, with 27 operating sites worldwide. The business employs around 1,500 people worldwide as well as is headquartered in Bloomington, Minn. The firm’s sales, adjusted to include recent acquisitions on a full-year basis, were approximately $430 million for its fiscal year ended March 31, 2015. Inge Thulin, 3M CEO said: “The acquisition of Capital Safety bolsters our personal safety platform and will build on our fundamental strengths in technology, manufacturing, global capabilities and brand.” 3M Company (NYSE:MMM) has the market capitalization of 99.93 Billion. Shares of firm plunged -1.44% to close at $157.54 with the total traded volume of 2.86 Million. The firm has current ratio of 2.50 for the most recent quarter.

Verizon Communications Inc. (NYSE:VZ) released that successful completion of its tender offer to buy all outstanding shares of AOL Inc for $50 per share in cash. The tender propose expired on June 22, 2015. Verizon subsequently completed the purchase of the remaining entitled AOL shares not purchased in the tender offer through a merger. As a result, AOL shares will no longer be traded on the NYSE, and AOL is now a wholly owned subsidiary of Verizon. In May 2015, Verizon Communications released that an contract to buy AOL, a key player in the digital content and advertising platforms space, for $50 per share, at an estimated total value of around $4.4 billion. Verizon Communications Inc. (NYSE:VZ) begun last trade with a price of $47.60 and throughout the trading session climbed at a high of $47.79. The day-trade ended with -1 % to $47.29. The stock is going forward to its 52 week low with 7.32% and lagging behind from its 52 week high price with -8.81%. VZ last month stock price volatility remained 0.98%.

BIND Therapeutics, Inc. (NASDAQ:BIND) released that U.S. FDA has approved the use of AstraZeneca’s Accurin AZD2811 in clinical examinations under an investigational new drug application. BIND Therapeutics is alliances with AstraZeneca on the development of AZD2811, an Aurora B Kinase inhibitor that has been shown to be active in both solid and hematological tumors in preclinical models. AstraZeneca is accountable for clinical development and commercialization and BIND is responsible for conducting clinical manufacturing through at least the end of phase 2 clinical trials. BIND Therapeutics, Inc. (NASDAQ:BIND) stock price closed at $5.92 with the total traded volume of 190694 shares. Its price to sales ratio ended at 9.14.